RxDoctor Payments Data

Arun Aneja, MD

Orthopaedic Trauma · Boston, MANPI 1316176134

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (35.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Synthes GmbH accounts for 62.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $13,378 and has fallen 54.5% since, to $6,082 in 2025.

$52,886in general payments, 2019–2025

Across 171 payments — averaging $309.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Synthes GmbH$33K
  • Medical Device Business Services, Inc.$9K
  • Stryker$6K
  • Johnson & Johnson$2K
  • Zimmer Biomet$1K
  • Paragon 28, Inc.$306
  • plus $480 from 6 others

What the payments were for

  • Consulting fees$7,60514%
  • Speaking & faculty fees$18,75035%
  • Travel & lodging$15,90630%
  • Food & beverage$10,62520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few orthopaedic trauma providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$167,989
Medicare patients
222
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl13$212
Quetiapine Fumarate14$212
Donepezil Hcl14$205

Paid to pharmacies, not to this prescriber.

Other orthopaedic trauma in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →